Format

Send to

Choose Destination
Clin Lung Cancer. 2015 Jan;16(1):24-32. doi: 10.1016/j.cllc.2014.09.005. Epub 2014 Sep 30.

Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.

Author information

1
Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: rmak@lroc.harvard.edu.
2
Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA.
3
Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.
4
Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; Department of Radiology, Brigham and Women's Hospital, Boston, MA.
5
Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.
6
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
7
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; Department of Biostatistics, Harvard School of Public Health, Boston, MA.
8
Lowe Center for Thoracic Oncology and Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA.
9
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL.

Abstract

BACKGROUND:

We analyzed outcomes after lung stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung-carcinoma (NSCLC) by histology and KRAS genotype.

PATIENTS AND METHODS:

We included 75 patients with 79 peripheral tumors treated with SBRT (18 Gy × 3 or 10 to 12 Gy × 5) at our institution from 2009 to 2012. Genotyping for KRAS mutations was performed in 10 patients. Outcomes were analyzed by the Kaplan-Meier method/Cox regression, or cumulative incidence method/Fine-Gray analysis.

RESULTS:

The median patient age was 74 (range, 46 to 93) years, and Eastern Cooperative Oncology Group performance status was 0 to 1 in 63%. Tumor histology included adenocarcinoma (44%), squamous cell carcinoma (25%), and NSCLC (18%). Most tumors were T1a (54%). Seven patients had KRAS-mutant tumors (9%). With a median follow-up of 18.8 months among survivors, the 1-year estimate of overall survival was 88%, cancer-specific survival (CSS) 92%, primary tumor control 94%, and freedom from recurrence (FFR) 67%. In patients with KRAS-mutant tumors, there was a significantly lower tumor control (67% vs. 96%; P = .04), FFR (48% vs. 69%; P = .03), and CSS (75% vs. 93%; P = .05). On multivariable analysis, histology was not associated with outcomes, but KRAS mutation (hazard ratio, 10.3; 95% confidence interval, 2.3-45.6; P = .0022) was associated with decreased CSS after adjusting for age.

CONCLUSION:

In this SBRT series, histology was not associated with outcomes, but KRAS mutation was associated with lower FFR on univariable analysis and decreased CSS on multivariable analysis. Because of the small sample size, these hypothesis-generating results need to be studied in larger data sets.

KEYWORDS:

Early stage; KRAS; Non–small-cell lung cancer; Stereotactic body radiotherapy

PMID:
25450872
PMCID:
PMC4427190
DOI:
10.1016/j.cllc.2014.09.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center